Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase 1b Study of CNTO 888 (an Anti-CCL 2 Monoclonal Antibody) in Combination With Chemotherapies for the Treatment of Subjects With Solid Tumors

NCT01204996 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.

NCT NCT01204996
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01204996 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase 1b Study of CNTO 888 (an Anti-CCL 2 Monoclonal Antibody) in Combination With Chemotherapies for the Treatment of Subjects With Solid Tumors
Lead sponsor
Centocor, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2010
Completion date
November 30, 2011
Enrollment
53 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

cancer